[{"id":"54e610ca-41de-4129-a9cc-28b0a7d31044","acronym":"SPARC-1","url":"https://clinicaltrials.gov/study/NCT04028245","created_at":"2021-01-29T07:19:33.502Z","updated_at":"2025-02-25T15:43:37.351Z","phase":"Phase 1","brief_title":"A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma","source_id_and_acronym":"NCT04028245 - SPARC-1","lead_sponsor":"Columbia University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • Ilaris (canakinumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 08/15/2019","start_date":" 08/15/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-07-09"},{"id":"dac8c5cc-c11e-498d-83e0-ff37aaef885f","acronym":"CANOPY-1","url":"https://clinicaltrials.gov/study/NCT03631199","created_at":"2021-01-18T17:50:06.187Z","updated_at":"2024-07-02T16:35:13.813Z","phase":"Phase 3","brief_title":"Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects","source_id_and_acronym":"NCT03631199 - CANOPY-1","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Ilaris (canakinumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 673","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 08/09/2021","primary_completion_date":" 08/09/2021","study_txt":" Completion: 06/07/2027","study_completion_date":" 06/07/2027","last_update_posted":"2024-03-20"},{"id":"cee602fb-6d33-45f6-b2f6-248a2d8fdf61","acronym":"PLATforM","url":"https://clinicaltrials.gov/study/NCT03484923","created_at":"2021-01-18T17:10:00.250Z","updated_at":"2024-07-02T16:35:22.981Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma","source_id_and_acronym":"NCT03484923 - PLATforM","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" LAG3","pipe":" | ","alterations":" BRAF wild-type","tags":["LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • Tabrecta (capmatinib) • spartalizumab (PDR001) • Ilaris (canakinumab) • ieramilimab (LAG525)"],"overall_status":"Completed","enrollment":" Enrollment 196","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2024-01-18"},{"id":"c4ec5c4c-4c79-4761-96b6-d089338bc996","acronym":"","url":"https://clinicaltrials.gov/study/NCT06038526","created_at":"2023-09-14T14:13:05.141Z","updated_at":"2024-07-02T16:35:36.912Z","phase":"Phase 2","brief_title":"Evaluation of Canakinumab in High-Risk Former-Smokers","source_id_and_acronym":"NCT06038526","lead_sponsor":"Peter Shields","biomarkers":" IL1B • CASP1","pipe":"","alterations":" ","tags":["IL1B • CASP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ilaris (canakinumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 09/30/2023","start_date":" 09/30/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-09-14"},{"id":"4c522063-8eba-4680-acba-ac43c6debdef","acronym":"","url":"https://clinicaltrials.gov/study/NCT02900664","created_at":"2021-01-18T14:14:11.436Z","updated_at":"2024-07-02T16:36:14.500Z","phase":"Phase 1","brief_title":"A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)","source_id_and_acronym":"NCT02900664","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD8 • FOXP3","pipe":" | ","alterations":" TILs","tags":["CD8 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • spartalizumab (PDR001) • nazartinib (EGF816) • CJM112 • Ilaris (canakinumab)"],"overall_status":"Completed","enrollment":" Enrollment 283","initiation":"Initiation: 08/23/2016","start_date":" 08/23/2016","primary_txt":" Primary completion: 03/17/2021","primary_completion_date":" 03/17/2021","study_txt":" Completion: 03/17/2021","study_completion_date":" 03/17/2021","last_update_posted":"2022-03-29"}]